

**Consolidated Financial Statements for the Third Quarter Ended December 31, 2025
FY2026 (April 1, 2025 - March 31, 2026) [UNAUDITED]**

February 13, 2026

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (PRIME section)
Code number: 2531
URL: <https://www.takara.co.jp/>
Company representative: Mutsumi Kimura, President
Contact: Masakazu Usami, General Manager of Public Relations & Investor Relations Dept.
TEL: (075)241-5124

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the Nine months ended December 31, 2025 (April 1, 2025 – December 31, 2025)

(1) Consolidated operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.			
	Nine months ended December 31, 2025	Nine months ended December 31, 2024	
	(Millions of yen)	(%)	(Millions of yen)
Net sales	291,529	9.2	266,935
Operating income (loss)	12,632	(15.3)	14,909
Ordinary income (loss)	12,555	(21.8)	16,066
Net income (loss) attributable to owners of the parent	10,557	(18.8)	13,002
Net income (loss) per share (Yen)	54.59		66.59
Fully diluted net income per share (Yen)	-		-
Note: Comprehensive income (loss)	5,888	(40.7)	9,932
			(70.9)

(2) Consolidated financial position

	As of December 31, 2025	As of March 31, 2025
	(Millions of yen)	(Millions of yen)
Total assets	497,091	477,587
Net assets	296,849	300,903
Equity ratio (%)	49.7	51.3
(Reference) Equity	246,836	245,228

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2025	Year ending March 31, 2026	Year ending March 31, 2026 (Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	31.00	-	31.00
Annual	31.00	-	31.00

Note: Correction of dividend forecast from the most recent dividend forecast: No

Note: The year-end dividend for FY2026 included a 100th anniversary commemorative dividend of ¥2.00

3. Forecast for the year ending March 31, 2026 (April 1, 2025 - March 31, 2026)

Note: Percentages indicated changes from the same period of the previous fiscal year.		
	Year ending March 31, 2026	
	(Millions of yen)	(%)
Net sales	392,000	8.1
Operating income (loss)	16,200	(21.3)
Ordinary income (loss)	15,700	(29.2)
Net income (loss) attributable to owners of the parent	11,100	(31.5)
Net income per share (Yen)	57.43	

Note: Correction of financial forecast from the most recent financial forecast: No

4. Others

(1) Material changes in subsidiaries during this period
(Changes in specified subsidiaries that caused a change in the scope of consolidation): Yes
Newly included: 1 (Name) Curio Bioscience, Inc.

(2) Accounting procedures specific to quarterly consolidated financial statements : No

(3) Changes in accounting policies, accounting estimates and retrospective restatement

- 1) Changes based on revisions of accounting standard: No
- 2) Changes other than ones based on revisions of accounting standard: No
- 3) Changes in accounting estimates: No
- 4) Restatement: No

(4) Number of outstanding shares (common stock)

- 1) Number of outstanding shares at the end of each period (Treasury stocks are included):

As of December 31, 2025 :	197,252,043 shares
As of March 31, 2025 :	197,252,043 shares
- 2) Number of treasury stocks at the end of each period:

As of December 31, 2025 :	4,378,161 shares
As of March 31, 2025 :	1,996,109 shares
- 3) Average number of outstanding shares in each period

Nine months ended December 31, 2025 :	193,409,925 shares
Nine months ended December 31, 2024 :	195,256,263 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: Yes (voluntary)

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

* Comment regarding appropriate use of earnings forecasts and other special notes
Forward-looking statements contained in this document are determined by the Takara Holdings Inc. (the "Company")
Based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future.